Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
What does it do?
Edwards Lifesciences makes the devices doctors use to fix broken heart valves — without cracking open your chest. Their most famous product, the SAPIEN valve, gets delivered through a thin tube inserted into your leg artery and guided up to your heart. This is a huge deal because the old alternative was open-heart surgery, which is risky and grueling, especially for elderly patients. They also make tools to repair the mitral and tricuspid valves on the left and right sides of the heart.
Heart valve disease affects millions of people globally, and the population is aging fast — meaning the pool of potential patients grows every year without Edwards having to do anything. Their minimally invasive approach has become the standard of care for aortic valve replacement, giving them a dominant market position in a field that is still expanding. Investors are watching closely as Edwards pushes into mitral and tricuspid valve repair, two markets that are earlier stage but potentially just as large.
How does it make money?
Edwards makes money almost entirely by selling its heart valve systems and related equipment to hospitals. Revenue hit $6.1 billion in the latest year, up from $5.4 billion the prior year — that's roughly 13% growth. The core SAPIEN family of transcatheter aortic valves (valves delivered through a tube, not open surgery) drives the bulk of sales. Their newer PASCAL and EVOQUE products for mitral and tricuspid valves are growing fast but still represent a smaller slice of total revenue.
Why do investors care?
The growth story here is straightforward: an aging global population means more people will need heart valve replacements, and Edwards is the market leader in the least invasive way to do it. The bigger bet is whether their PASCAL and EVOQUE devices can replicate that dominance in mitral and tricuspid repair — two large, underpenetrated markets where competitors like Abbott are also fighting hard. For the thesis to work, Edwards needs to keep winning regulatory approvals, expanding into new patient groups, and defending its turf against well-funded rivals.
Deep Dive
MemberA full investor briefing on Edwards Lifesciences Corporation — history, leadership, risks, and outlook.